Merck & Co., Inc. MRK
We take great care to ensure that the data presented and summarized in this overview for Merck & Co., Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding MRK
View all-
Vanguard Group Inc Valley Forge, PA250MShares$24.3 Billion0.52% of portfolio
-
Black Rock Inc. New York, NY207MShares$20.2 Billion0.59% of portfolio
-
State Street Corp Boston, MA119MShares$11.6 Billion0.56% of portfolio
-
Wellington Management Group LLP Boston, MA75.8MShares$7.39 Billion1.55% of portfolio
-
Geode Capital Management, LLC Boston, MA59.2MShares$5.76 Billion0.55% of portfolio
-
Morgan Stanley New York, NY44.4MShares$4.33 Billion0.37% of portfolio
-
Bank Of America Corp Charlotte, NC38.9MShares$3.79 Billion0.37% of portfolio
-
Northern Trust Corp Chicago, IL26.9MShares$2.62 Billion0.51% of portfolio
-
Jpmorgan Chase & CO New York, NY26.8MShares$2.62 Billion0.25% of portfolio
-
Legal & General Group PLC London, X023.6MShares$2.3 Billion0.57% of portfolio
Latest Institutional Activity in MRK
Top Purchases
Top Sells
About MRK
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.
Insider Transactions at MRK
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Aug 05
2024
|
Chirfi Guindo Chief Marketing Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
17,412
-30.13%
|
$2,002,380
$115.2 P/Share
|
Aug 05
2024
|
Chirfi Guindo Chief Marketing Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
36,901
+38.97%
|
$4,243,615
$115.2 P/Share
|
May 04
2024
|
Dalton Smart SVP Fin. - Global Controller |
SELL
Payment of exercise price or tax liability
|
Direct |
302
-6.38%
|
$38,354
$127.51 P/Share
|
May 04
2024
|
Dalton Smart SVP Fin. - Global Controller |
BUY
Exercise of conversion of derivative security
|
Direct |
612
+11.46%
|
$77,724
$127.51 P/Share
|
May 04
2024
|
Michael A Klobuchar EVP - Chief Strategy Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
437
-1.82%
|
$55,499
$127.51 P/Share
|
May 04
2024
|
Michael A Klobuchar EVP - Chief Strategy Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
887
+3.56%
|
$112,649
$127.51 P/Share
|
May 04
2024
|
Richard R. De Luca EVP&Pres, Merck Animal Heallth |
SELL
Payment of exercise price or tax liability
|
Direct |
13,360
-8.16%
|
$1,696,720
$127.51 P/Share
|
May 04
2024
|
Richard R. De Luca EVP&Pres, Merck Animal Heallth |
BUY
Exercise of conversion of derivative security
|
Direct |
27,126
+14.21%
|
$3,445,002
$127.51 P/Share
|
May 04
2024
|
Johannes Jacobus Oosthuizen President, U.S. Market |
SELL
Payment of exercise price or tax liability
|
Direct |
450
-1.85%
|
$57,150
$127.51 P/Share
|
May 04
2024
|
Johannes Jacobus Oosthuizen President, U.S. Market |
BUY
Exercise of conversion of derivative security
|
Direct |
912
+3.62%
|
$115,824
$127.51 P/Share
|
May 03
2024
|
Dalton Smart SVP Fin. - Global Controller |
SELL
Payment of exercise price or tax liability
|
Direct |
845
-9.98%
|
$108,160
$128.26 P/Share
|
May 03
2024
|
Dalton Smart SVP Fin. - Global Controller |
BUY
Exercise of conversion of derivative security
|
Direct |
2,046
+18.8%
|
$261,888
$128.26 P/Share
|
May 02
2024
|
Joseph Romanelli President, Human Health Int?l |
SELL
Payment of exercise price or tax liability
|
Direct |
1,115
-5.11%
|
$142,720
$128.8 P/Share
|
May 02
2024
|
Joseph Romanelli President, Human Health Int?l |
BUY
Exercise of conversion of derivative security
|
Direct |
2,262
+9.39%
|
$289,536
$128.8 P/Share
|
May 02
2024
|
Dalton Smart SVP Fin. - Global Controller |
SELL
Payment of exercise price or tax liability
|
Direct |
131
-4.3%
|
$16,768
$128.8 P/Share
|
May 02
2024
|
Dalton Smart SVP Fin. - Global Controller |
BUY
Exercise of conversion of derivative security
|
Direct |
381
+11.11%
|
$48,768
$128.8 P/Share
|
Feb 14
2024
|
Robert M Davis Chairman, CEO & President |
SELL
Open market or private sale
|
Direct |
85,021
-19.62%
|
$10,627,625
$125.4 P/Share
|
Feb 14
2024
|
Robert M Davis Chairman, CEO & President |
BUY
Exercise of conversion of derivative security
|
Direct |
85,021
+16.4%
|
$6,206,533
$73.73 P/Share
|
Feb 14
2024
|
Caroline Litchfield EVP & CFO |
SELL
Open market or private sale
|
Direct |
38,291
-42.93%
|
$4,786,375
$125.5 P/Share
|
Feb 14
2024
|
Caroline Litchfield EVP & CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
38,291
+30.03%
|
$2,220,878
$58.08 P/Share
|
Last 12 Months Summary
Grant, award, or other acquisition | 233K shares |
---|---|
Exercise of conversion of derivative security | 432K shares |
Payment of exercise price or tax liability | 34.1K shares |
---|---|
Open market or private sale | 410K shares |